Skip to main
LMAT

LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular (LMAT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

LeMaitre Vascular is a financially stable medical device company that is actively seeking growth opportunities through potential M&A activities and new market expansion. With a strong track record of operational performance and a focus on open vascular and cardiac surgery, the company is well-positioned to continue its growth trajectory in the coming years. Additionally, their efforts to comply with EU regulations and increase their sales force demonstrate a commitment to sustained growth through both organic and strategic means.

Bears say

LeMaitre Vascular is expected to continue delivering consistent double-digit organic top line growth, with material margin expansion and strong cash flow, leading to a 25x multiple to our FY/26 adjusted EBITDA estimate and a $275 million net cash assumption in 12 months from now. Despite potential short-term weakness, the company has a solid balance sheet with $367 million in cash and marketable securities and only $169 million in debt, and is making strong progress in international regulatory approvals, including securing Canada and expected launches in Korea, Brazil, Vietnam, and India in 2027 for its largest product, Artegraft.

LeMaitre Vascular (LMAT) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeMaitre Vascular (LMAT) Forecast

Analysts have given LeMaitre Vascular (LMAT) a Buy based on their latest research and market trends.

According to 5 analysts, LeMaitre Vascular (LMAT) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $110.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $110.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeMaitre Vascular (LMAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.